Morphometric analysis of fibrovascular pigment epithelial detachments treated with ranibizumab and aflibercept. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Karampelas, Michael; Syriga, Maria; Petrou, Petros; Georgalas, Ilias; Papaconstantinou, Dimitrios; Brouzas, Dimitrios
• Is Part Of: European journal of ophthalmology. Volume 32:Issue 1(2022)
• Page Start: 347
• Page End: 355
• Publication Date: 2022-01
• Subjects: Age-related macular degeneration -- retina -- optics/refraction/instruments -- retina - medical therapies -- pharmacology; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/11206721211005706
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To assess fibrovascular pigment epithelial detachments (PED) and their response to two different anti-VEGF agents using optical coherence tomography (OCT) morphometric analysis. Methods: Seventy-three consecutive, treatment-naïve eyes with fibrovascular PED (>125 μm) treated with ranibizumab or aflibercept were retrospectively included. A custom-made software was used to manually segment and calculate PED maximum height, base area, volume and internal reflectivity at baseline, after three injections and 1 year. Results: Visual acuity (VA) change was 2 ETDRS letters ± 7.6 after three injections and 3.2 ETDRS letters ± 10.3 at 1 year. There was no significant difference between VA changes amongst the two drugs. At 1 year, anti-VEGF treatment resulted in a mean reduction of 125 μm in maximum PED height, of 2.26 mm 2 in base area and of 0.54 mm 3 in volume with a corresponding increase in reflectivity. These changes were more prominent in the aflilbercept group. The observed PED and VA changes at year 1 were strongly correlated with their values at baseline and after three injections. Conclusions: Anti-VEGF treatment resulted in a reduction of all PED dimensions and a corresponding increase in optical reflectivity. Higher, larger and more hypo-reflective PEDs demonstrated a better anatomical response, especially with aflibercept, but this was not correlated with VA.